*HomeU.S. Government Accountability Office*
Menu

      close


          
          
                          	
				
				
	
	
					Reports & Testimonies
									
																				
				
				
	
	
								Reports & Testimonies
													
																												
																						
							
																Recommendations Database
							
																												
																						
							
																Month in Review
							
																												
																						
							
																Order Copies
							
																												
																						
							
																Restricted Reports
							
																												
																						
							
																View Topics
							
																												
																						
							
																View Agencies
							
																												
																						
							
																Bid Protests & Appropriations Law
									
																				
				
				
	
	
								Bid Protests & Appropriations Law
													
																												
																						
							
																Bid Protests
							
																												
																						
							
																Appropriations Law
							
																												
																						
							
																Federal Vacancies Reform Act
							
																												
																						
							
																Other Legal
							
																												
																						
							
																About
									
																				
				
				
	
	
								About
													
																												
																						
							
																What GAO Does
							
																												
																						
							
																U.S. Comptroller General
							
																												
																						
							
																Careers
							
																												
																						
							
																Contact UsFor Congress
                                
                          
        
                Press Center
                                
                          
        
                Careers
                                
                          
        
                BlogSearch Breadcrumb
        Home
                            Reports & Testimonies
                            Regenerative Medicine: Therapeutic Applications, Challenges, and Policy Options
    Regenerative Medicine:
                          Therapeutic Applications, Challenges, and Policy Options **GAO-23-105430**
        Published: Jul 13, 2023. Publicly Released: Jul 13, 2023.Jump To:
    Jump ToElder Abuse
          Services for Older Adults
          State and Local-Level Drivers and Trends
          State and Local Fiscal Projections
          Federal Borrowing
          Managing the Debt
          Summary of Funding Provisions
          Auditing the Government's Books
          Unpacking the Financial Report
          Highlights
          Recommendations
          Background
          About This Work
          About This Work
          Trends
          About the Center
          Why It's High Risk
          What Remains To Be Done
          Key Reports
          Newest COVID-Related Reports
          AI Use Cases
          Flood Insurance
          Past Pandemic-Related Reports
          CARES Act Oversight Reports
          All COVID-19 Reports
          Report Suspected Fraud
          Subjects
          How to Get Notified
          Past Reports
          Public Health Threats
          Explore the FY 2022 and 2023 Funds
          Lessons Learned
          Agency Reports
          Recent Reports
          Recommendations
          Supplemental Material
          Full Report
          Additional Data
          View Decision
          Downloads
          Previously Identified Actions
          Related Pages
          Associated Agencies
          Tough Choices and Opportunities Ahead
          Americas Fiscal Future Key Areas
          Retirement Security Key Areas
          Current List
          About The High Risk List
          Area Ratings
          Previous High Risk Products
          Search Federal Vacancies
          Past Federal Vacancies
          Violation Letters
          About the Yellow Book
          Advisory Council
          Related Resources
          Comment Letters
          Related Publications
          Contacts and Resources
          Major Issues Facing the Nation
          Meeting Strategic Challenges
          Additional Resources
          Resources
          GAO Contacts
          Mission Teams
          Operations and Staff Offices
          Organization Chart
          Why a Career at GAO?
          Am I Qualified?
          Company Culture
          Reasonable Accommodations
          Video Gallery
          Paid Internships
          Student Volunteers
          Professional Development Program
          Advancement
          Executive Candidate Program
          Summer Associates
          Externships
          Benefits
          Contacts
                    Fast Facts
              Regenerative medicine restores or replaces human cells, tissues, or organs affected by disease. This may eventually help cure many conditions that are currently considered difficult to treat.

For example, a patient's own cells could be used to create a personalized organ, which could eliminate the possibility that a patient's body will reject a donated organ.

However, there are challenges with developing regenerative medicine technologies. We offer 11 policy options to help address such challenges. For example, federal agencies could help by supporting public-private partnerships that can share costs for manufacturing facilities.

Illustration showing an outline of a human body made up of lines and dots and surrounded by icons that have charts on them
Skip to Highlights
Highlights
  What GAO Found

Regenerative medicine offers the hope of being able to restore or replace cell, tissue, and organ functions affected by disease, injury, or aging. This may eventually help manage or cure many conditions that are currently considered chronic, untreatable, or terminal.

**Examples of Diseases and Regenerative Medicine Therapies That Might Address Them**

**

GAO identified many challenges that may affect the development and use of regenerative medicine technologies and therapies including:

**Challenges related to standardization.** Standards are rules, conditions, guidelines, or agreed-upon practices that are adopted within an industry to provide developers with a common framework and promote consistency. Developing regenerative medicine standards is challenging because these technologies and therapies are complex and rapidly evolving. In addition, standards require consensus from stakeholders, which may be difficult to obtain.

**Challenges related to regulation.** The Food and Drug Administration (FDA) ensures the safety, efficacy, and security of human medical products in the U.S. through regulation. Regenerative medicine faces challenges related to regulation, including difficulty navigating a complex regulatory framework, uncertainty over which regulatory pathway is most appropriate for certain emerging technologies and therapies, and staffing shortages at FDA and collaborating agencies.

**Challenges related to manufacturing.** Manufacturing is the creation of products from starting materials, in a way that is generally consistent and reproducible. It is a key step for many emerging technologies and therapies, but the cells, tissues, and organs used for regenerative medicine are complex and difficult to manufacture at scale. Other challenges to manufacturing include a lack of infrastructure and difficulty ensuring quality and consistency.

GAO developed 11 policy options that could help address the challenges or enhance the benefits of regenerative medicine. These policy options are provided to inform policymakers of potential actions to address the policy challenges identified in this technology assessment. They identify possible actions by policymakers, which include Congress, federal agencies, state and local governments, academic and research institutions, and industry. Policymakers would need to consider the impacts these new technologies will have on existing federal programs that are already strained. We suggested possible federal components for the policy options.

**Selected Policy Options to Mitigate Challenges Associated with Regenerative Medicine Technologies and Therapies**

**Selected policy Option**
			**Opportunities**
			**Considerations****Invest in standards development.**
			(report p. 26)

			This policy option could help address the challenge that standards require consensus.
			Could streamline standards development, which may, in turn, accelerate innovation, increase product safety and reliability, accelerate regulatory review, and decrease costs of regenerative medicine therapies.
			Existing organizations may not include all stakeholders, and stakeholders may hesitate to accept standards created without their input.
				Industry stakeholders may hesitate to adopt standards if they perceive it will cost them a controlling position in the market.
				Standards should be appropriately flexible to allow for innovation, while still being detailed and specific enough to support manufacturing of consistent, quality products.**Provide opportunities for increased interactions between regulatory experts (at FDA or in industry) and smaller companies, especially early in the development process** (report p. 32)

			This policy option could help address the lack of access to regulatory expertise.
			May provide more timely advice and avoid unnecessary delays or uncertainty by pursuing the wrong regulatory pathways or submitting data that do not meet regulatory requirements.
			May require additional resources to bolster the workforce of regulatory scientists at FDA or public-private partnerships.
				FDA may be limited in its ability to advise companies early in the process so as not to create a conflict of interest.**Consider whether changes to the framework for evaluating combination products and medical devices to accommodate emerging technologies and therapies may be necessary.**(report p. 33)

			This policy option could help address whether current regulatory pathways are sufficient for emerging technologies and therapies.
			May encourage innovators, researchers, and developers of new products to provide valuable feedback to regulators.
			Coordinating among stakeholders to consider changes to regulatory pathways may be time- and resource-intensive.
				If such consideration leads to recommended changes to the framework, statutory and regulatory changes may be necessary.**Provide more oversight and feedback to suppliers to increase consistency in starting materials** (report p. 40)

			This policy option could help address inconsistency in starting materials for manufacturing.
			May accelerate manufacturing by reducing variation in input materials.
				May reduce the risk of failure during product development.
			Starting material suppliers may lack incentives to follow standards if they lead to higher costsSource: GAO.  |  GAO-22-105274

Why GAO Did This Study

Regenerative medicine represents a paradigm shift in the medical field because it aims to restore or supplement function, rather than just treating symptoms, and opens the door for personalized therapies. GAO conducted an assessment of current and emerging regenerative medicine technologies and therapeutic applications. This report examines (1) current and emerging regenerative medicine technologies and therapies and their potential benefits, (2) challenges that hinder their development and use, and (3) policy options that could help enhance benefits and mitigate challenges associated with these technologies and therapies. GAO reviewed scientific and policy literature and other key reports; convened a 3-day expert meeting; interviewed subject matter experts and stakeholder groups including government agencies, such as the Department of Health and Human Services, non-government organizations, industry, academia, end user groups such as patient groups; and conducted site visits. GAO is identifying policy options in this report.

For more information, contact Karen L. Howard at (202) 512-6888 or howardk@gao.gov.

Full Report
    Highlights Page (2 pages)
              Full Report (55 pages)
              Accessible PDF (55 pages)
GAO Contacts
    
      Karen Howard
            
            Director
      
            howardk@gao.gov
      
            (202) 512-6888
Office of Public Affairs
    
      Chuck Young
            
            Managing Director
      
            youngc1@gao.gov
      
            (202) 512-4800
Topics
    
      Health CareBiologicsEmerging technologiesEngineeringHealth care standardsManufacturingMedicineProduct developmentStem cellsTherapyPatient care
                                                      MultimediaPhoto showing a woman filling medical test tubes using a droplet syringe
          Blog Post
              A Revolutionary Medical Technology Could Help Millions—If We Play Our Cards Right
            Tuesday, July 18, 2023
      
            A rapidly evolving field known as regenerative medicine could provide new treatments for cancer...
 Receive GAO Updates
  Stay informed as we add new reports & testimonies.

    GAO Logo
      U.S. Government Accountability Office


                                   Column 1
                            Press Center
                              Contact Us
                              Inspector General
                              Restricted Reports
                              Column 2
                            Copyright & Terms of Use
                              Privacy Policy
                              Accessibility
                              Sitemap
                              Column 3
                            FOIA Requests
                              Scam Alerts
                              No FEAR Act Data
                              Health Care Advisory Committees